Skip over navigation
Banner
Directory
Directory Search
Jobs
Job Search Post a Job
Patient
Patient Resources Drug Development
History
Genealogy
Toons & Teasers
Industry
 Directory
 Toons & Teasers
Quick Links
 Directory
 Job Search
 Toons & Teasers
 Advertising
 
Facilities
 

EquipNet Auction: Teva Facility Closure: Lab, Packaging, Utility & Warehouse Equipment - July 19

Check Out Our Newest Cartoon: "COVID-19 Vacations Redux, West Coast"

North American Biotech Roadshow Featuring Grad Students, Post-Docs & Start-Up “Do’s & Don’ts”


Iowa Life Science Industry Directory

NuWest LabTemps: Find your next direct hire or contract employment.

Banner Advertising

Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and delayed by COVID-19, to be launched in 2022 replacing IowaLifeScience.com. Regrettably, we are working with reduced staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved directory upon the launch of the new site. We apologize for the inconvenience.

NewLink Genetics Corporation


NewLink Genetics Corporation
2503 South Loop Drive, Suite 5100
Ames, IA 50010
NewLink Genetics Corporation
 
Phone: (515) 296-5555
Fax: (515) 296-3520
Year Established:  1999
Employees: 82
Ticker: NLNK
Exchange: NASDAQ
Main Contact: Jack Henneman, CFO
 
Other Contacts:  Eugene Kennedy, M.D., CMO
Gabriela R Rossi, Ph.D., VP, Biologics Development
Brian Wiley, CCO
Mario Mautino, Ph.D., VP, Drug Discovery & IP
Lisa DeLuca, PhD,, VP, Regulatory Affairs
Nicholas N. Vahanian, M.D., Co-Founder & President
Charles J. Link, Jr., M.D., Co-Founder, Chairman, CEO & CSO
 
Company Description
NewLink Genetics (formerly BioProtection Systems Corp.) is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink's product candidates are designed with an objective to harness multiple components of the innate immune system to combat cancer, either as a monotherapy or in combination with current treatment regimens, without incremental toxicity. NewLink's lead product candidate, algenpatucel-L (HyperAcute Pancreas) cancer immunotherapy is being studied in a Phase 3 clinical trial in surgically resected pancreatic cancer patients (patient information is available at http://www.pancreaticcancer-clinicaltrials.com) under a Special Protocol Assessment with the U.S. Food and Drug Administration. NewLink and its collaborators have completed patient enrollment for a Phase 2 clinical trial evaluating its tergenpumatucel-L (HyperAcute Lung) cancer immunotherapy product candidate for non-small cell lung cancer and is now recruiting patients in a Phase 2B/3 clinical trial in this indication. NewLink has completed patient enrollment in a Phase 2 clinical trial for its HyperAcute Melanoma cancer immunotherapy product candidate. NewLink also is developing indoximod (NLG8189 or D-1MT), a small molecule, orally bioavailable product candidate from NewLink's proprietary indoleamine (2, 3) dioxygenase, or IDO, pathway inhibitor technology. Through NewLink's collaboration with the National Cancer Institute, NewLink is studying indoximod in various chemotherapy and immunotherapy combinations in two Phase 1B/2 safety and efficacy clinical trials.


Main Industry Directory

 
Email thie page to a friend. Email This Page
to a Friend
Print this page. Print This
Page
© 1997 - 2022 Info.Resource, Inc. All rights reserved.
Privacy Policy . Cookie Policy . Terms of Use . About . Advertising

IowaLifeScience.com is owned and published by Info.Resource, Inc.